EDITORIAL
Exciting changes
Yali Friedman
ARTICLES
Bacterial proteins: A new class of cancer therapeutics
Ananda Mohan Chakrabarty
Industrial biotechnology – Markets and industry structure
Gunter Festel, Christian Detzel, Ruth Maas
Options to Change Medicare Payment for Outpatient Prescription Drugs and Biotechnology Products
Thomas Barker, Maia Larsson
The Emergence of Bio-Clusters in Egypt and South Africa
Ramazan Uctu, Nirvana Shanalee Pillay
Patent litigation in India and interim injunctions — An evolving jurisprudence
Rajashree Sharma, Dinesh Kumar Sharma
FROM THE BOARDROOM
Digital health investment opportunities abound, but standouts deliver disruptive change
G. Steven Burrill
Strategies for Collaboration Agreements Focusing on Innovation
Pamela Cox
Biomarketing strategy and tactics 101 PART I of III
Dimitris Dogramatzis
FROM THE CLASSROOM
The University of Colorado Certificate Program in Bioinnovation and Entrepreneurship:
Madhavan Parthasarathy, David Forlani, Arlen Meyers
LEGAL AND REGULATORY UPDATES
EU Legal & Regulatory Update
Ewan Grist
Post-Grant Review: The Good, the Bad and the Ugly for Biotechnology Companies
Smitha Uthaman, Deborah Lu, Thomas Kowalski
BOOK REVIEWS
Book Review: Constructing and Deconstructing Patents by Irah H. Donner
David B. Orange
Book Review: Plunkett’s Biotech & Genetics Industry Almanac 2012
Barry J. Marenberg
For more, see the Journal of Commercial Biotechnology at http://CommercialBiotechnology.com
# # #
The Journal of Commercial Biotechnology is a quarterly peer-reviewed professional journal which focuses on the commercial, legal, and regulatory issues affecting biotechnology, biopharmaceutical, agrochemical, and environmental companies.
